Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated vs standard Allergovit 6-Grasses dose escalation in pediatric grass pollen allergy
2018-000548-25Phase 2Completed
- Sponsor
- Allergopharma
- Start
- Apr 2018
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Allergovit in seasonal allergic rhinitis (SAR) and allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by Allergopharma. Primary endpoints: Safety and tolerability of accelerated dose escalation and Safety and tolerability compared with standard escalation. Started Apr 2018; status: completed.
02
Drugs
Allergovit
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2018-000548-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000548-25.